全球細胞和基因治療合約開發和生產組織（CDMO）市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

細胞和基因治療 CDMO 市場預計將從 2025 年的 74.7 億美元成長到 2034 年的 340.4 億美元，2026 年至 2034 年的複合年成長率為 18.36%。

隨著製藥和生物技術公司擴大將複雜的生產流程外包，全球細胞和基因治療CDMO市場正在快速成長。對癌症、罕見疾病和遺傳疾病等先進療法的投資增加，推動了對專業CDMO的需求。細胞和基因療法的複雜性需要先進的設施和監管方面的專業知識，這進一步促進了外包夥伴關係的建立。

關鍵促進因素包括臨床研發管線的擴展和基因修飾療法監管核准數量的增加。高昂的生產成本和對規模化生產的需求進一步加劇了對經驗豐富的合約研發產量機構（CDMO）的依賴。此外，生技公司與CDMO之間的策略合作正在加快產品開發進程並提高供應鏈效率。

未來，隨著病毒載體生產技術、自動化技術和低溫運輸物流的進步，市場預計將持續擴張。全球臨床試驗活動的增加和法規結構的支持也將繼續為合約研發生產機構（CDMO）創造強勁的發展機會。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球細胞與基因治療合約開發與生產（CDMO）市場：依階段分類

• 市場分析、洞察與預測
• 臨床前階段
• 臨床

第5章 全球細胞與基因治療合約開發與生產（CDMO）市場：依產品類型分類

• 市場分析、洞察與預測
• 基因治療（體外、體內）
• 基因改造細胞療法（CAR T 細胞療法、CAR-NK 細胞療法、TCR-T 細胞療法等）
• 細胞療法

第6章：全球細胞與基因治療合約開發與生產（CDMO）市場：依適應症分類

• 市場分析、洞察與預測
• 腫瘤學
• 感染疾病
• 神經系統疾病
• 罕見疾病
• 其他

第7章 全球細胞與基因治療合約開發與生產（CDMO）市場：按地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Lonza
  • Catalent Inc
  • Cytiva
  • Samsung Biologics
  • Thermo Fisher Scientific Inc
  • WuXi AppTec
  • AGC Biologics
  • OmniaBio
  • Charles River Laboratories

The Cell And Gene Therapy CDMO Market size is expected to reach USD 34.04 Billion in 2034 from USD 7.47 Billion (2025) growing at a CAGR of 18.36% during 2026-2034.

The global cell and gene therapy CDMO market is growing rapidly as pharmaceutical and biotechnology companies increasingly outsource complex manufacturing processes. Rising investments in advanced therapies for cancer, rare diseases, and genetic disorders are fueling demand for specialized contract development and manufacturing organizations (CDMOs). The complexity of cell and gene therapies requires advanced facilities and regulatory expertise, encouraging outsourcing partnerships.

Key drivers include expanding clinical pipelines and the growing number of regulatory approvals for gene-modified therapies. High manufacturing costs and the need for scalability further boost reliance on experienced CDMOs. Additionally, strategic collaborations between biotech firms and CDMOs are accelerating product development timelines and improving supply chain efficiency.

In the future, the market is expected to expand with improvements in viral vector production, automation technologies, and cold chain logistics. Increasing global clinical trial activity and supportive regulatory frameworks will continue to create strong opportunities for CDMOs.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Phase

• Pre-Clinical
• Clinical

By Product Type

• Gene Therapy (Ex-Vivo, In-Vivo)
• Gene-Modified Cell Therapy (Car T-Cell Therapies, Car-Nk Cell Therapy, Tcr-T Cell Therapy, Other)
• Cell Therapy

By Indication

• Oncology
• Infectious Diseases
• Neurological Disorders
• Rare Diseases
• Others

COMPANIES PROFILED

• Lonza, Catalent Inc, Cytiva, Samsung Biologics, Thermo Fisher Scientific Inc, WuXi AppTec, AGC Biologics, OmniaBio, Charles River Laboratories
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CELL AND GENE THERAPY CDMO MARKET: BY PHASE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Phase
• 4.2. Pre-Clinical Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Clinical Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CELL AND GENE THERAPY CDMO MARKET: BY PRODUCT TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Product Type
• 5.2. Gene Therapy (Ex-Vivo, In-Vivo) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Gene-Modified Cell Therapy (Car T-Cell Therapies, Car-Nk Cell Therapy, Tcr-T Cell Therapy, Other) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Cell Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CELL AND GENE THERAPY CDMO MARKET: BY INDICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Indication
• 6.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Neurological Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Rare Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CELL AND GENE THERAPY CDMO MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Phase
  • 7.2.2 By Product Type
  • 7.2.3 By Indication
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Phase
  • 7.3.2 By Product Type
  • 7.3.3 By Indication
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Phase
  • 7.4.2 By Product Type
  • 7.4.3 By Indication
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Phase
  • 7.5.2 By Product Type
  • 7.5.3 By Indication
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Phase
  • 7.6.2 By Product Type
  • 7.6.3 By Indication
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL CELL AND GENE THERAPY CDMO INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Lonza
  • 9.2.2 Catalent Inc
  • 9.2.3 Cytiva
  • 9.2.4 Samsung Biologics
  • 9.2.5 Thermo Fisher Scientific Inc
  • 9.2.6 WuXi AppTec
  • 9.2.7 AGC Biologics
  • 9.2.8 OmniaBio
  • 9.2.9 Charles River Laboratories